113 related articles for article (PubMed ID: 26632104)
1. A visualization method measuring the performance of biomarkers for guiding treatment decisions.
Yang H; Tang R; Hale M; Huang J
Pharm Stat; 2016; 15(2):152-64. PubMed ID: 26632104
[TBL] [Abstract][Full Text] [Related]
2. Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers.
Zhang Y; Trippa L; Parmigiani G
Biometrics; 2016 Jun; 72(2):414-21. PubMed ID: 26575199
[TBL] [Abstract][Full Text] [Related]
3. The use of novel diagnostics to individualize immunosuppression following transplantation.
Schlickeiser S; Boës D; Streitz M; Sawitzki B
Transpl Int; 2015 Aug; 28(8):911-20. PubMed ID: 25611562
[TBL] [Abstract][Full Text] [Related]
4. The impact of companion diagnostic device measurement performance on clinical validation of personalized medicine.
Li M; Yu T; Hu YF
Stat Med; 2015 Jun; 34(14):2222-34. PubMed ID: 25779099
[TBL] [Abstract][Full Text] [Related]
5. Testing for treatment-biomarker interaction based on local partial-likelihood.
Liu Y; Jiang W; Chen BE
Stat Med; 2015 Nov; 34(27):3516-30. PubMed ID: 26084729
[TBL] [Abstract][Full Text] [Related]
6. Designing precision medicine trials to yield a greater population impact.
Zhao YQ; LeBlanc ML
Biometrics; 2020 Jun; 76(2):643-653. PubMed ID: 31598964
[TBL] [Abstract][Full Text] [Related]
7. Impact of Biomarkers on Personalized Medicine.
Carrigan P; Krahn T
Handb Exp Pharmacol; 2016; 232():285-311. PubMed ID: 26330258
[TBL] [Abstract][Full Text] [Related]
8. Personalized screening intervals for biomarkers using joint models for longitudinal and survival data.
Rizopoulos D; Taylor JM; Van Rosmalen J; Steyerberg EW; Takkenberg JJ
Biostatistics; 2016 Jan; 17(1):149-64. PubMed ID: 26319700
[TBL] [Abstract][Full Text] [Related]
9. Individual Biomarkers Using Molecular Personalized Medicine Approaches.
Zenner HP
ORL J Otorhinolaryngol Relat Spec; 2017; 79(1-2):7-13. PubMed ID: 28231575
[TBL] [Abstract][Full Text] [Related]
10. Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.
Blaus A; Madabushi R; Pacanowski M; Rose M; Schuck RN; Stockbridge N; Temple R; Unger EF
Circulation; 2015 Oct; 132(15):1425-32. PubMed ID: 26459078
[TBL] [Abstract][Full Text] [Related]
11. The residual-based predictiveness curve: A visual tool to assess the performance of prediction models.
Casalicchio G; Bischl B; Boulesteix AL; Schmid M
Biometrics; 2016 Jun; 72(2):392-401. PubMed ID: 26676377
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the predictiveness of a continuous marker.
Huang Y; Sullivan Pepe M; Feng Z
Biometrics; 2007 Dec; 63(4):1181-8. PubMed ID: 17489968
[TBL] [Abstract][Full Text] [Related]
13. Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers.
Shih WJ; Lin Y
Stat Med; 2018 Feb; 37(5):687-709. PubMed ID: 29205435
[TBL] [Abstract][Full Text] [Related]
14. On evaluating how well a biomarker can predict treatment response with survival data.
Mboup B; Blanche P; Latouche A
Pharm Stat; 2020 Jul; 19(4):410-423. PubMed ID: 31943737
[TBL] [Abstract][Full Text] [Related]
15. On optimal treatment regimes selection for mean survival time.
Geng Y; Zhang HH; Lu W
Stat Med; 2015 Mar; 34(7):1169-84. PubMed ID: 25515005
[TBL] [Abstract][Full Text] [Related]
16. Personalized Medicine: Genomics Trials in Oncology.
Hayes DF; Schott AF
Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
[TBL] [Abstract][Full Text] [Related]
17. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
Do K; O'Sullivan Coyne G; Chen AP
Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
[TBL] [Abstract][Full Text] [Related]
18. [The relevance of biomarkers for personalised medicine].
Großhennig A; Benda N; Koch A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1480-8. PubMed ID: 24084852
[TBL] [Abstract][Full Text] [Related]
19. Estimating the Optimal Personalized Treatment Strategy Based on Selected Variables to Prolong Survival via Random Survival Forest with Weighted Bootstrap.
Shen J; Wang L; Daignault S; Spratt DE; Morgan TM; Taylor JMG
J Biopharm Stat; 2018; 28(2):362-381. PubMed ID: 28934002
[TBL] [Abstract][Full Text] [Related]
20. Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.
Lin JA; He P
Br Med Bull; 2015 Jun; 114(1):17-27. PubMed ID: 25921239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
